Scancell Holdings PLC. (SCNLF)

[Gift_Horse]

CENKOS SECURITIES PROVIDES $1.94 TARGET PRICE

Analyst Navid Malik, Head of Life Sciences Research at Cenkos Securities, maintains his BUY rating for Scancell's shares with a target price based on expected news flow of $1.94* per share.

*127.89 pence = £1.28 = $1.94 [pounds and dollar amounts are rounded and based on today's exchange rate].

NAVID MALIK:
Dr. Navid Malik is the Head of Life Sciences Research for Cenkos Securities Plc. in the UK, and has been one of the most influential analysts in the UK and Europe over the last decade, covering the life sciences industry worldwide. In 2011, Dr. Malik was awarded two Starmine Awards (awarded each year by Thomson Reuters and the Financial Times): Number One Stock Picker in the European Pharmaceutical Sector, and Number Two Stock Picker in the UK and Ireland Healthcare Sector. Dr. Malik has built life science teams and franchises at multiple large financial institutions in London, which completed IPOs and secondary stock offerings for small biotech and life sciences companies totaling over $700 million in recent years, and which also initiated research coverage on dozens of small life sciences companies in addition to covering large pharmaceutical, biologics and healthcare companies. Dr. Malik holds a PhD in Drug Delivery within Pharmaceutical Sciences, as well as degrees in Biomedical Sciences Research (M.Sc.) and Biochemistry and Physiology (B.Sc., joint honors). Dr. Malik also holds an MBA in finance.